Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus FULVICIN P G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus FULVICIN P G.
AMPHOTEC vs FULVICIN P/G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Binds to microtubule-associated proteins, disrupting mitotic spindle formation and inhibiting fungal cell division.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
250 mg orally twice daily for tinea infections; 500 mg orally twice daily for onychomycosis. Administer with a fatty meal to enhance absorption.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal elimination half-life: 9–24 hours (mean ~16 hours). Clinical context: prolonged half-life allows once-daily dosing; steady-state achieved within 2–3 days.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Renal (largely unchanged, <1% as metabolites); biliary/fecal (minor). Approximately 36% of a dose is excreted in urine within 6 hours, and up to 50% within 72 hours.
Category C
Category C
Antifungal
Antifungal